Home/Pipeline/BEIZRAY (Albumin Solubilized Docetaxel)

BEIZRAY (Albumin Solubilized Docetaxel)

Oncology (Solid Tumors)

Pre-registrationLicensed for US market (505(b)(2))N/A

Key Facts

Indication

Oncology (Solid Tumors)

Phase

Pre-registration

Status

Licensed for US market (505(b)(2))

Company

Zydus Lifesciences

About Zydus Lifesciences

Zydus Lifesciences is a mission-driven global pharmaceutical company dedicated to creating healthier, happier communities worldwide. Its strategy is built on a dual engine of deep expertise in complex generics and a robust innovation pipeline in novel chemical entities (NCEs), biologics, and vaccines. Key achievements include launching Lipaglyn, the first NCE from an Indian research pipeline, and pioneering biosimilars like Exemptia (adalimumab), while maintaining strong financial growth and a vast commercial footprint.

View full company profile

Therapeutic Areas

Cardio-Metabolic Inflammation and Immunology Neurosciences Oncology Rare Diseases Infectious Diseases

Other Oncology (Solid Tumors) Drugs

Drug	Company	Phase	Status
OATD-02	Molecure	Phase I	Active, recruiting
Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)	Athebio	Pre-clinical	Active Partnership
AB821	Asher Biotherapeutics	Preclinical	Active
Undisclosed Preclinical Pipeline	OncoResponse	Preclinical	Active
Undisclosed Platform Program	Da Zen Theranostics	Pre-clinical	Active
Compound42	Abbmira Therapeutics	Pre-clinical	Active
Clinical Decision Support Service	Curematch	Commercial	Active
CV6-168	CV6 Therapeutics	Phase 1a	Active
Chemophototherapy (CPT)	POP Biotechnologies	Pre-clinical	Active
HRD Testing Solution	SeqOne Genomics	Commercial	Active
Platform Validation & Partnership Development	SingleCell Biotechnology	Pre-clinical	Active
Undisclosed	Y-Trap	Preclinical	Active